

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



30<sup>th</sup> November, 2021

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
NSE Code – SUNPHARMA

BSE Ltd,  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001.  
BSE Code– 524715

Sub: Intimation about Settlement of DUSA Pharmaceuticals, Inc., with Biofrontera Inc. and its associate companies

Dear Sirs,

We refer to our earlier intimation to the Stock Exchanges, dated 11<sup>th</sup> July, 2018, wherein we informed you, *inter alia*, that DUSA Pharmaceuticals, Inc., (“DUSA”), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, filed a lawsuit against Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (together “Biofrontera”), in the United States District Court for the District of Massachusetts, alleging misappropriation of trade secrets, tortious interference of contract and unfair trade practices (the “Litigation”).

We would like to update you that DUSA has reached a settlement with Biofrontera resolving the Litigation. Pursuant to the terms of the settlement, DUSA will receive US\$22.5 millions from Biofrontera. Additional details regarding the settlement are confidential.

As required by law, the parties have filed a notice of settlement with the U.S. District Court, and, after thirty days, if Biofrontera complies with the terms of settlement agreement, the U.S. District Court will enter an order dismissing the Litigation.

Yours faithfully,  
For Sun Pharmaceutical Industries Limited

Ashok I Bhuta  
Compliance Officer